NCT02951195View on ClinicalTrials.gov

A Study Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

January 31, 2018

Study Completion Date

January 31, 2018

Conditions

Cystic Fibrosis

Interventions

DRUG

VX-152

Tablet for oral administration.

DRUG

TEZ/IVA

Fixed-dose combination tablet for oral administration.

DRUG

IVA

Tablet for oral administration.

DRUG

Placebo

Placebo matched to VX-152.

DRUG

Placebo

Placebo matched to VX-152/TEZ/IVA triple combination (TC).

Trial Locations (16)

Unknown

Birmingham

La Jolla

Los Angeles

Orlando

Chicago

Peoria

St Louis

Chapel Hill

Akron

Cleveland

Portland

Philadelphia

Charleston

Fort Worth

Houston

Madison

All Listed Sponsors

lead

Vertex Pharmaceuticals Incorporated

INDUSTRY

NCT02951195 - A Study Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis | Biotech Hunter | Biotech Hunter